今天早上的press release https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. [ 链接：cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.pfizer.com%2F&esheet=52522826&newsitemid=20211105005260&lan=en-US&anchor=Pfizer+Inc.&index=1&md5=2983fd45de871ed7d2e6cacaa5c2bb3b ] (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (3/389 hospitalized with no deaths), compared to 7.0% of patients who received placebo and were hospitalized or died (27/385 hospitalized with 7 subsequent deaths). The statistical significance of these results was high (p<0.0001). Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 subsequent deaths), with high statistical significance (p<0.0001). In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 (1.6%) deaths in patients who received placebo.
和Merck 的临床经验结果对比： Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo.
Re.Pfizer 已经说会给穷国便宜价格。 Pfizer said it planned to offer poorer countries the drug at discounted prices. The company has been in talks with a United Nations-backed nonprofit, the Medicines Patent Pool, to allow the pill to be made and sold inexpensively in such countries; Merck has already reached a similar deal.
好像不用往下做了，赶快跟merck抢钱去 Based on the recommendation of the Independent Data Monitoring Committee and in consultation with the FDA, Pfizer said it has halted the EPID—HR study due to overwhelming efficacy. Pfizer will use the data to support a rolling submission to the FDA for EUA of the drug.
Re.Pfizer 已经说会给穷国便宜价格。 Pfizer said it planned to offer poorer countries the drug at discounted prices. The company has been in talks with a United Nations-backed nonprofit, the Medicines Patent Pool, to allow the pill to be made and sold inexpensively in such countries; Merck has already reached a similar deal. Rutang48 发表于 2021-11-05 13:01
好像不用往下做了，赶快跟merck抢钱去 Based on the recommendation of the Independent Data Monitoring Committee and in consultation with the FDA, Pfizer said it has halted the EPID—HR study due to overwhelming efficacy. Pfizer will use the data to support a rolling submission to the FDA for EUA of the drug. vitd120 发表于 2021-11-05 13:05
这个世界怪的很，ivermectin也是很好的 protease inhibitor， 也有许多RCT证明疗效，却被称为马药，备受攻击。开拓药业的Proxalutamide不仅可以抑制transmembrane protease serine 2 (TMPRSS2)， 还可以抑制ACE2，7月份就在巴拉圭拿到了EUA，至今却无人问津。辉瑞做个类似的protease inhibitor，就被狂捧。 "ivermectin blocked more than 85% of 3CLpro activity of SARS-CoV-2. Although the anti-viral activity of ivermectin mediated through the blocking of α/β1 importin19,20,21,22,23 is established, herein we report the inhibitory effects of ivermectin on 3CLpro enzyme of SARS-CoV-2, suggesting additional anti-viral mechanism of ivermectin towards SARS-CoV-2". https://www.nature.com/articles/s42003-020-01577-x
这个世界怪的很，ivermectin也是很好的 protease inhibitor， 也有许多RCT证明疗效，却被称为马药，备受攻击。开拓药业的Proxalutamide不仅可以抑制transmembrane protease serine 2 (TMPRSS2)， 还可以抑制ACE2，7月份就在巴拉圭拿到了EUA，至今却无人问津。辉瑞做个类似的protease inhibitor，就被狂捧。 "ivermectin blocked more than 85% of 3CLpro activity of SARS-CoV-2. Although the anti-viral activity of ivermectin mediated through the blocking of α/β1 importin19,20,21,22,23 is established, herein we report the inhibitory effects of ivermectin on 3CLpro enzyme of SARS-CoV-2, suggesting additional anti-viral mechanism of ivermectin towards SARS-CoV-2". https://www.nature.com/articles/s42003-020-01577-x
这个世界怪的很，ivermectin也是很好的 protease inhibitor， 也有许多RCT证明疗效，却被称为马药，备受攻击。开拓药业的Proxalutamide不仅可以抑制transmembrane protease serine 2 (TMPRSS2)， 还可以抑制ACE2，7月份就在巴拉圭拿到了EUA，至今却无人问津。辉瑞做个类似的protease inhibitor，就被狂捧。 "ivermectin blocked more than 85% of 3CLpro activity of SARS-CoV-2. Although the anti-viral activity of ivermectin mediated through the blocking of α/β1 importin19,20,21,22,23 is established, herein we report the inhibitory effects of ivermectin on 3CLpro enzyme of SARS-CoV-2, suggesting additional anti-viral mechanism of ivermectin towards SARS-CoV-2". https://www.nature.com/articles/s42003-020-01577-x
herbs 发表于 2021-11-05 14:14
民科又来了。。。。 拜托你仔细去读一下正文，文章里面IVM达到对3CL蛋白酶的抑制作用的浓度是多少？50 uM 正常吃IVM (200 ug/kg)的时候体内能达到多大的浓度呢(C max）？大概是50 nM，也就是0.05 uM https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1889 所以说要达到这个对3CL蛋白酶抑制的浓度需要吃多少药呢？答案是200mg/kg，50公斤体重的人需要吃10克，80公斤体重的人需要吃16克才能治病。 那么，IVM对人类的致死剂量又是多少呢？大概是5 mg/kg，有效药量的40分之一。。。 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/
https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. [ 链接：cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.pfizer.com%2F&esheet=52522826&newsitemid=20211105005260&lan=en-US&anchor=Pfizer+Inc.&index=1&md5=2983fd45de871ed7d2e6cacaa5c2bb3b ] (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (3/389 hospitalized with no deaths), compared to 7.0% of patients who received placebo and were hospitalized or died (27/385 hospitalized with 7 subsequent deaths). The statistical significance of these results was high (p<0.0001). Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 subsequent deaths), with high statistical significance (p<0.0001). In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 (1.6%) deaths in patients who received placebo.
参加试验的都是有高危因素的病人。出现症状3天以内：药物组3/389住院，无人死亡；安慰剂组27/385住院，7人死亡。出现症状5天以内：药物组6/607住院，无人死亡；安慰剂组41/612人住院，10人死亡。
————————————————
我前面的一个帖子已经讲过，Pfizer的这个蛋白酶抑制剂理论上的concern比Merck的小（导致病毒出现新突变和患者本身的致癌/致畸），有效的抗病毒浓度EC 50也更低。press release里面的信息有限，等到申请EUA的时候会有更多消息被公开，那个时候我们可以更好地比较两个现有的抗病毒药物。不过从press release来看，这是个非常非常正面的消息。
https://forums.huaren.us/showtopic.html?topicid=2744374
🔥 最新回帖
这个临床试验中的入选的病人是有症状五天以内，PCR确诊三天以内开始吃药（paxlovid 300 mg/ritonavir 100 mg BID for 5 days). 如果以后批准后，病人一有症状就赶紧测试，约医生，有结果了医生开药希望来得及。
第三针和第一第二针是一样的，不是针对变种的新疫苗。其实现有疫苗产生的抗体是具有一点广谱性的，所以对变种也有一定效果，但没有像对野生病株那么有效。效果低怎么办，那就靠量取胜。打了booster以后，抗体大量产生，对Delta的效果也就不错了，看过辉瑞的一个press release，也有90%左右的保护。但当然随着时间，抗体量会慢慢降低，效果就渐渐差了。所以FDA在审批的时候，只推荐给老年人和高危健康人群和高危职业人群，而不是大众。
疫苗对Delta也有效，只是50%多，不如针对原始病株95%那么高的有效率。而且现在有第三针，第三针是针对变种做了调整的，应该有效率更高，过一段时间就知道具体数据了。
🛋️ 沙发板凳
据报道这个月辉瑞就要申请EUA啦。
长期来看这个应该比merck那个卖的好，钱又被pfizer赚了
有免疫记忆在，疫苗对重症的保护没那么容易衰减，打疫苗当然有意义，你的T细胞有没有见过抗原肯定是不一样的。
我记得我以前说过不止一次，公共健康意义上的fully vaccinated就是两针，没必要再加。除了需要接触高危人群的一线医务人员，健康成年人的booster和未成年人的疫苗不应该强制，主要靠自愿。
能开发出这样的药，赚钱不是很应该的吗？
在有些人眼里，赚钱就是罪恶，只有和他/她一样穷的才是好人。
你是通过啥悟出来的？著名的新的一共才俩药，原有的不算，一个还没投入市场使用，一个才中期刚过。
既然有药了，我觉得T细胞没见过也没啥
谁说不让赚了，我只是说他会赚钱这个fact
他可以多多的赚，只要药厂和政府保证大家能及时吃到就行
常年小股东觉得是的啊
尽管有了Tamiflu, 医学界还是鼓励大家去打flu shot 啊。
没有强制啊，给大家一个option就行
小股东和小股东握个手。
原来你有conflict of interest!
近期肯定不行
哈，401K 里有一个关于药厂的ETF， 算什么conflict of interest. 我就不信如果你做投资，diversify 的portfolio， 就没有一点药厂的股票？
不管，你benefit了就算
疫苗和药物是锦上添花的关系，双重保险
要说这个，最大的conflict of interest 就是不管疫苗也好，口服药也好，让这个pandemic快快结束，才是我最大的interest， 最大的benefit
你意思是要等到over counter后？那不知多少年。我问的不是这个，我问的是在刚出来时还是prescription的时候，怎么办。
这是哪门子的conflict，这种又拿不到钱
你下次推疫苗得挂个签名档： pfizer小小股东
疫苗便宜，药贵。之前MRK那个药是疫苗好几倍贵，效果还不如疫苗。你猜政府和保险公司喜欢哪个。
两针应该还是不行，我看好几种其他病的疫苗full course都是三针，比如肝炎疫苗，不是没道理的。第三针这个booster应该还是比较关键的。
肯定得阳性了才能开啊
他们也许还会做那种预防的，就是家里有人阳性了，其他人可以开，但是这些都还早呢。
现在好多人有症状不去测试就自己在家隔离了,那以后就是得测试阳性后才能开药，可是谁给开，约医生也不是马上约到的，很关心程序
我也是啊！
这种药都是越早吃越有效，第0-1天吃最有效，发病5天以后再吃作用可能就比较小了
最好是阳性了就能在附近领到小药包。不过美国这干啥都慢慢的，不知道会是啥情况
你有SP500 index fund吗？或者ETF？这些里面都有Pfizer，如果是index fund的constituent, 不必declare。
SP500混在一起都稀释成啥了能一样嘛
但好像价格不便宜，5天$700-$800，保险公司肯定等你确诊后才会批。
Tesla这波大涨，光市值涨幅就有$ 320 billion，好的消息面也就是一个Hertz的10万辆订单，简直太匪夷所思了!
去年是盼疫苗，今年盼特效药
和巨无霸比起来，Pfizer也是小药企。
这有啥不明的，不是很正常的吗，clinical trial时的病人都是千挑万选最对症的，上了市医生对症的擦边的都给开了试试，overall效果肯定比trial差
PFE 也就在发达国家赚点钱。
Pfizer这个公司这次确实立了大功了，最好的疫苗和最好的特效药。真是十年不鸣，一鸣惊人。但是估计也赚不了很多钱，普通老百姓都觉得你就该廉价或者免费给我，那政府也不会愿意付大钱给医药公司。而且联合国也会要求几乎免费供应穷国。医药公司胳膊拧不过大腿。医药公司赚钱还是主要靠治慢性病，能吃一辈子那种药。
这马屁拍的。最好的疫苗宣传时95%的有效率，结果不防传染，抗体半年就降到要打第三针，副作用种类繁多。
95%有效率是针对alpha，很难理解吗？
Pfizer疫苗现在也有95%的有效率，针对原始病株，也能防传染。原始病株现在不是几乎绝迹了吗？
针对Delta确实有效率不高，因为Delta是疫苗研制将近一年以后才出现的，你这是要求Pfizer未卜先知吗？而且这次出booster不就是为了提高针对Delta和其他变异的有效率吗？
另外，是不是最好的疫苗，那是要横向比较。如果没有疫苗比Pfizer好，那Pfizer就是最好的疫苗。在美国现在Pfizer就是唯一一款批准可以给青少年使用的。Moderna的都被拒了。
不难理解啊！就是类似，这最好的特效药呢，下一波gamma来了发现有效性降低了，可以解释为这个86%的有效性只是针对delta的，对吧
看股价就行了从2020年初到这消息出来前， Pfizer股价可是没有跑赢大盘的。return 只有大盘一半多点
Re.Pfizer 已经说会给穷国便宜价格。 Pfizer said it planned to offer poorer countries the drug at discounted prices. The company has been in talks with a United Nations-backed nonprofit, the Medicines Patent Pool, to allow the pill to be made and sold inexpensively in such countries; Merck has already reached a similar deal.
好像不用往下做了，赶快跟merck抢钱去
Based on the recommendation of the Independent Data Monitoring Committee and in consultation with the FDA, Pfizer said it has halted the EPID—HR study due to overwhelming efficacy. Pfizer will use the data to support a rolling submission to the FDA for EUA of the drug.
那你说说最好的是哪一个？科兴？
不知道便宜卖给中国不，卖的话中国可以开放了
跟 ivermectin 效果一样，就是贵好多
你对于有些人的理解能力的要求应该现实一点
紧急授权和正式批准使用还是不一样的吧。
万一得上保险要是不好就自费吃吧。这病说不清楚，早吃上踏实。
eua了就能用，之前疫苗很久都是eua
但是有点担心他们一开始eua会不会只给高危人群 （跟单抗一样），不是立刻给所有人
不过单抗生产起来比较麻烦，还要养老鼠。pfizer和merck这俩应该是批量生产毫无压力的
如果政府全买走了，想自费也买不到。。我也愿意出700块屯着
Urgent care马上看吧。flu也是差不多的。不过flu有时候也测不出来然后医生不给开药……我一个同事就是，然后又约了家庭医生测出来了才吃上tamiflu
你这么牛要不你去开发下包治百病的神药呗……
"ivermectin blocked more than 85% of 3CLpro activity of SARS-CoV-2. Although the anti-viral activity of ivermectin mediated through the blocking of α/β1 importin19,20,21,22,23 is established, herein we report the inhibitory effects of ivermectin on 3CLpro enzyme of SARS-CoV-2, suggesting additional anti-viral mechanism of ivermectin towards SARS-CoV-2". https://www.nature.com/articles/s42003-020-01577-x
没有资本支持，就是只能做成一个迷
这又不是饭， 没确诊为什么要吃
我当然是说确诊了再吃啊。原帖不是说确诊了也要保险批不知道几天，我说那确诊了就跟医生说立刻自费吃，也没有几个钱。。。
对，也想问，covid 测试也有false negative， 真不好关键的前几天都错过了
嗯
非常关心这个程序，反正要是真得了，肯定不会等保险批，直接自己掏钱，当然过后保险能报销更好
感觉怀疑自己得了，肯定得赶紧找起码两家验，万一false negative呢，然后有了确诊才能有机会批准治疗。
民科又来了。。。。
拜托你仔细去读一下正文，文章里面IVM达到对3CL蛋白酶的抑制作用的浓度是多少？50 uM
正常吃IVM (200 ug/kg)的时候体内能达到多大的浓度呢(C max）？大概是50 nM，也就是0.05 uM
https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1889
所以说要达到这个对3CL蛋白酶抑制的浓度需要吃多少药呢？答案是200mg/kg，50公斤体重的人需要吃10克，80公斤体重的人需要吃16克才能治病。
那么，IVM对人类的致死剂量又是多少呢？大概是5 mg/kg，有效药量的40分之一。。。
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/
希望大家看到，连闲话名人小浣熊都说了booster和未成年人疫苗主要靠自愿，不应该强制。
什么意思？？我不是第一天这么说吧！
真的，有这个ETF不如买科技股的，可比那几个官司不断的药厂要挣钱的多。